President & CEO, Form Bio
Michelle Chen, Ph.D., is a prominent biotech executive currently serving as the President, CEO, and Board Member of Form Bio. A spin-off from Colossal Biosciences, Form Bio focuses on leveraging AI for genetic medicine and genome engineering. Previously, Dr. Chen was the Chief Business Officer at Insilico Medicine, where she spearheaded growth through AI-driven drug discovery and high-value partnerships.
With a career spanning R&D, product management, and commercial leadership, she has held senior roles at major organizations including Roche, Merck, BioMarin, and Agilent Technologies. Dr. Chen is an expert in strategy, M&A, and fundraising, having successfully led company formations and delivered a five-fold increase in market capitalization for a public company within three years. She holds a Ph.D. in Biochemistry from the University of Washington, conducted postdoctoral research at UC San Francisco, and completed bioinformatics training at Stanford University.